DE102007003148A1 - Gentechnisch modifizierte Bakteriophagen, insbesondere zur Bekämpfung von pathogenen Prokaryonten bzw. ihrer pathologischen Wirkung, sowie deren Verwendung und Herstellung - Google Patents

Gentechnisch modifizierte Bakteriophagen, insbesondere zur Bekämpfung von pathogenen Prokaryonten bzw. ihrer pathologischen Wirkung, sowie deren Verwendung und Herstellung Download PDF

Info

Publication number
DE102007003148A1
DE102007003148A1 DE102007003148A DE102007003148A DE102007003148A1 DE 102007003148 A1 DE102007003148 A1 DE 102007003148A1 DE 102007003148 A DE102007003148 A DE 102007003148A DE 102007003148 A DE102007003148 A DE 102007003148A DE 102007003148 A1 DE102007003148 A1 DE 102007003148A1
Authority
DE
Germany
Prior art keywords
phage
bacteriophage
prokaryotes
pathogenic
prokaryotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102007003148A
Other languages
German (de)
English (en)
Inventor
Markus von Dr.rer.nat. Nickisch-Rosenegk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Priority to DE102007003148A priority Critical patent/DE102007003148A1/de
Priority to PCT/EP2007/011409 priority patent/WO2008086881A1/fr
Publication of DE102007003148A1 publication Critical patent/DE102007003148A1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
DE102007003148A 2007-01-15 2007-01-22 Gentechnisch modifizierte Bakteriophagen, insbesondere zur Bekämpfung von pathogenen Prokaryonten bzw. ihrer pathologischen Wirkung, sowie deren Verwendung und Herstellung Ceased DE102007003148A1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE102007003148A DE102007003148A1 (de) 2007-01-15 2007-01-22 Gentechnisch modifizierte Bakteriophagen, insbesondere zur Bekämpfung von pathogenen Prokaryonten bzw. ihrer pathologischen Wirkung, sowie deren Verwendung und Herstellung
PCT/EP2007/011409 WO2008086881A1 (fr) 2007-01-15 2007-12-21 Bactériophages génétiquement modifiés, destinés notamment à la lutte contre des procaryotes pathogènes et leur effet pathologique, leur production et leur utilisation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007002114.5 2007-01-15
DE102007002114 2007-01-15
DE102007003148A DE102007003148A1 (de) 2007-01-15 2007-01-22 Gentechnisch modifizierte Bakteriophagen, insbesondere zur Bekämpfung von pathogenen Prokaryonten bzw. ihrer pathologischen Wirkung, sowie deren Verwendung und Herstellung

Publications (1)

Publication Number Publication Date
DE102007003148A1 true DE102007003148A1 (de) 2008-07-17

Family

ID=39434255

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102007003148A Ceased DE102007003148A1 (de) 2007-01-15 2007-01-22 Gentechnisch modifizierte Bakteriophagen, insbesondere zur Bekämpfung von pathogenen Prokaryonten bzw. ihrer pathologischen Wirkung, sowie deren Verwendung und Herstellung

Country Status (2)

Country Link
DE (1) DE102007003148A1 (fr)
WO (1) WO2008086881A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040465A1 (en) * 2009-04-30 2012-02-16 Pherecydes Pharma Modification of the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061804A1 (fr) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Agents toxiques et ribozymes specifiques de tissu et specifiques de pathogene
WO2001044456A2 (fr) * 1999-12-17 2001-06-21 The University Of Nottingham Modification de micro-organismes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7013219B2 (en) * 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2002034892A1 (fr) * 2000-10-25 2002-05-02 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Bacteriophage modifie comprenant une modification non lytique et exprimant un gene kil
JP4336814B2 (ja) * 2003-08-04 2009-09-30 農工大ティー・エル・オー株式会社 ジンクフィンガー蛋白質を用いる標的核酸の検出方法
US7455840B2 (en) * 2003-11-19 2008-11-25 The Scripps Research Institute Compositions and methods to reduce mutagenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061804A1 (fr) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Agents toxiques et ribozymes specifiques de tissu et specifiques de pathogene
WO2001044456A2 (fr) * 1999-12-17 2001-06-21 The University Of Nottingham Modification de micro-organismes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Babalova et al. 1968
Bruttin und Brüssow, 2005
Chibani-Chennoufi et al., 2004
Hagens, S. (u.a.): The Therapy of experimental Pseudomonas infections with a nonreplicating gene- tically modified phage. In: Antimicrob. Agents Chemother., 2004, Vol. 48, S. 3817-3822
Hagens, S. (u.a.): The Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. In: Antimicrob. Agents Chemother., 2004, Vol. 48, S. 3817-3822 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040465A1 (en) * 2009-04-30 2012-02-16 Pherecydes Pharma Modification of the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof
US9029153B2 (en) * 2009-04-30 2015-05-12 Pherecydes Pharma Modification of the genome of a lytic bacteriophage by immobilizing said bacteriophage in the host bacterium thereof

Also Published As

Publication number Publication date
WO2008086881A1 (fr) 2008-07-24

Similar Documents

Publication Publication Date Title
Reardon Bacterial arms race revs up
Brüssow What is needed for phage therapy to become a reality in Western medicine?
Allen et al. Treatment, promotion, commotion: antibiotic alternatives in food-producing animals
Monk et al. Bacteriophage applications: where are we now?
Meile et al. Engineering therapeutic phages for enhanced antibacterial efficacy
FI3307872T3 (fi) Menetelmiä ja koostumuksia nukleiinihappojen ja rna-pohjaisten antimikrobien tehokkaaseen antamiseen
JP2020525049A5 (fr)
JP2020528762A5 (fr)
Fage et al. Delivery of CRISPR-Cas systems using phage-based vectors
Squires Bacteriophage therapy for management of bacterial infections in veterinary practice: what was once old is new again
Barrangou et al. CRISPR-directed microbiome manipulation across the food supply chain
Aminov et al. Application of bacteriophages
DE60315636T2 (de) Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen
Bhattacharjee et al. Programmable removal of bacterial pathogens using CRISPR-Cas9 system
DE102007003148A1 (de) Gentechnisch modifizierte Bakteriophagen, insbesondere zur Bekämpfung von pathogenen Prokaryonten bzw. ihrer pathologischen Wirkung, sowie deren Verwendung und Herstellung
Novick Antibacterial particles and predatory bacteria as alternatives to antibacterial chemicals in the era of antibiotic resistance
Yan et al. Effects of environmental disinfection on microbial population and resistance genes: A case study of the microecology within a panda enclosure
Squires Bacteriophage therapy for challenging bacterial infections: Achievements, limitations and prospects for future clinical use by veterinary dermatologists
Gill et al. Bacteriophages and phage-derived products as antibacterial therapeutics
Morin Community ecology and the genetics of interacting species
Gutiérrez et al. Bacteriophages: The Enemies of Bad Bacteria Are Our Friends!
Fernbach Synthetic Biology for Genetically Engineered Bacteriophages to Target Infectious Diseases
Nir-Paz et al. Bacteriophage therapy in humans
DE4222289C1 (de) Verfahren und Mittel zur Instabilisierung von viralen Quasi-Spezies-Verteilungen unter Vermeidung von Resistenzphänomenen
Sarmah et al. Isolation and Characterization of Clostridium perfringens from Suspected Cases of Necrotic Enteritis (NE) in Broiler Chicken

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
R016 Response to examination communication
R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final

Effective date: 20120322